PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor

Pharmacogenet Genomics. 2013 Nov;23(11):636-42. doi: 10.1097/FPC.0b013e3283655091.

Authors

Ugur Hodoglugil¹, Michelle W Carrillo, Joan M Hebert, Niki Karachaliou, Rafael C Rosell, Russ B Altman, Teri E Klein

Affiliation

¹ Departments of aGenetics bBioengineering, Stanford University Medical Center, Stanford, California, USA cBreakthrough Cancer Research Unit, Pangaea Biotech, Dexeus University Institute dMedical Oncology Service, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Barcelona, Spain.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antineoplastic Agents / antagonists & inhibitors*
Antineoplastic Agents / therapeutic use
Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / genetics*
Clinical Trials, Phase III as Topic
Drug Resistance, Neoplasm / genetics
ErbB Receptors / genetics*
Genetic Variation
Humans
Molecular Targeted Therapy
Pharmacogenetics
Polymorphism, Single Nucleotide
Prospective Studies
Protein Kinase Inhibitors / therapeutic use

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Biomarkers, Tumor
Protein Kinase Inhibitors
EGFR protein, human
ErbB Receptors

Grants and funding